ANAPTYSBIO, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
ANAPTYSBIO, INC. (ANAB) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $5.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-09-21
- ANAPTYSBIO, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $5.38M, a 7810.29% increase from fiscal 2024.
- ANAPTYSBIO, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $68.00K, a 98.91% decline from fiscal 2023.
- ANAPTYSBIO, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $6.21M, a 87.19% increase from fiscal 2022.
- ANAPTYSBIO, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $3.32M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $5.38M 10-K · filed 2026-03-03 | |
| 2024-12-31 | $68.00K 10-KT · filed 2026-09-21 | $7.06M 10-K · filed 2025-02-27 |
| 2023-12-31 | $6.21M 10-K · filed 2026-03-03 | |
| 2022-12-31 | $3.32M 10-K · filed 2025-02-27 | |
| 2021-12-31 | -$8.09M 10-K · filed 2024-03-11 | |
| 2020-12-31 | $3.39M 10-K · filed 2023-03-01 | |
| 2019-12-31 | $4.41M 10-K · filed 2022-03-07 | |
| 2018-12-31 | $4.39M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $1.55M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $814.00K 10-K · filed 2019-02-28 | |
| 2015-12-31 | -$13.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |